|
1
|
Cunningham D, Atkin W, Lenz HJ, et al:
Colorectal cancer. Lancet. 375:1030–1047. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Verdecchia A, Francisci S, Brenner H, et
al: EUROCARE-4 Working Group: Recent cancer survival in Europe: a
2000–02 period analysis of EUROCARE-4 data. Lancet Oncol.
8:784–796. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
No authors listed. Efficacy of adjuvant
fluorouracil and folinic acid in colon cancer. International
Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT)
investigators. Lancet. 345:939–944. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rutman RJ, Cantarow A and Paschkis KE:
Studies in 2-acetylaminofluorene carcinogenesis. III. The
utilization of uracil-2-C14 by preneoplastic rat liver and rat
hepatoma. Cancer Res. 14:119–123. 1954.PubMed/NCBI
|
|
5
|
Thomas DM and Zalcberg JR: 5-fluorouracil:
a pharmacological paradigm in the use of cytotoxics. Clin Exp
Pharmacol Physiol. 25:887–895. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Noordhuis P, Holwerda U, Van der Wilt CL,
et al: 5-Fluorouracil incorporation into RNA and DNA in relation to
thymidylate synthase inhibition of human colorectal cancers. Ann
Oncol. 15:1025–1032. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang N, Yin Y, Xu SJ and Chen WS:
5-Fluorouracil: mechanisms of resistance and reversal strategies.
Molecules. 13:1551–1569. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Giacchetti S, Perpoint B, Zidani R, et al:
Phase III multicenter randomized trial of oxaliplatin added to
chronomodulated fluorouracil-leucovorin as first-line treatment of
metastatic colorectal cancer. J Clin Oncol. 18:136–147.
2000.PubMed/NCBI
|
|
9
|
Douillard JY, Cunningham D, Roth AD, et
al: Irinotecan combined with fluorouracil compared with
fluorouracil alone as first-line treatment for metastatic
colorectal cancer: a multicentre randomised trial. Lancet.
355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
De Wever O, Pauwels P, De Craene B, et al:
Molecular and pathological signatures of epithelial-mesenchymal
transitions at the cancer invasion front. Histochem Cell Biol.
130:481–494. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rosanò L, Cianfrocca R, Spinella F, et al:
Acquisition of chemoresistance and EMT phenotype is linked with
activation of the endothelin A receptor pathway in ovarian
carcinoma cells. Clin Cancer Res. 17:2350–2360. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kurokawa M, Ise N, Omi K, et al: Cisplatin
influences acquisition of resistance to molecular-targeted agents
through epithelial-mesenchymal transition-like changes. Cancer Sci.
104:904–911. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Y, Sun Y, Chen L, et al: miRNA-200c
increases the sensitivity of breast cancer cells to doxorubicin
through the suppression of E-cadherin-mediated PTEN/Akt signaling.
Mol Med Rep. 7:1579–1584. 2013.PubMed/NCBI
|
|
15
|
Huang XY, Ke AW, Shi GM, et al:
αB-crystallin complexes with 14-3-3ξ to induce
epithelial-mesenchymal transition and resistance to sorafenib in
hepatocellular carcinoma. Hepatology. 57:2235–2247. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhou Q, Zeng R, Xu C, et al: Erbin
inhibits TGF-β1-induced EMT in renal tubular epithelial cells
through an ERK-dependent pathway. J Mol Med (Berl). 90:563–574.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Conti B, Minutolo A, Arciello M and
Balsano C: Are Hedgehog and Wnt/β-catenin pathways involved in
hepatitis C virus-mediated EMT? J Hepatol. 58:636–637. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu X, Zhou Y, Xie C, et al: Genome-wide
screening reveals an EMT molecular network mediated by Sonic
hedgehog-Gli1 signaling in pancreatic cancer cells. PLoS One.
7:e431192012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shan D, Chen L, Njardarson JT, et al:
Synthetic analogues of migrastatin that inhibit mammary tumor
metastasis in mice. Proc Natl Acad Sci USA. 102:3772–3776. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shan D, Chen L, Wang D, Tan YC, Gu JL and
Huang XY: The G protein G alpha(13) is required for growth
factor-induced cell migration. Dev Cell. 10:707–718. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang S and Huang XY: Ca2+ influx through
L-type Ca2+ channels controls the trailing tail contraction in
growth factor-induced fibroblast cell migration. J Biol Chem.
280:27130–27137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Todosi AM, Gavrilescu MM, Aniţei GM, et
al: Colon cancer at the molecular level - usefulness of
epithelial-mesenchymal transition analysis. Rev Med Chir Soc Med
Nat Iasi. 116:1106–1111. 2012.PubMed/NCBI
|
|
23
|
Bhangu A, Wood G, Mirnezami A, Darzi A,
Tekkis P and Goldin R: Epithelial mesenchymal transition in
colorectal cancer: Seminal role in promoting disease progression
and resistance to neoadjuvant therapy. Surg Oncol. 21:316–323.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jin H, Gong W, Zhang C and Wang S:
Epigallocatechin gallate inhibits the proliferation of colorectal
cancer cells by regulating Notch signaling. Onco Targets Ther.
6:145–153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang FX, Deng AJ, Li M, Wei JF, Qin HL and
Wang AP: (3S)-1,2,3,4-Tetrahydro-β-carboline-3-carboxylic acid from
Cichorium endivia. L induces apoptosis of human colorectal cancer
HCT-8 cells. Molecules. 18:418–429. 2012. View Article : Google Scholar : PubMed/NCBI
|
